Evaluation of the Reactogenicity, Safety and Immunogenicity of the Domestic Influenza Inactivated Split FLU-M Vaccine in Immunization Adults aged 18–60 Years
https://doi.org/10.31631/2073-3046-2018-17-1-20-24
Abstract
This article presents the results of a simple, blind, randomized, placebo-controlled, single-center, prospective research of the reactogenicity, safety, and immunogenicity of the domestic influenza inactivated split vaccine «Flu-M» in immunization of the adult population of 18–60 years old. Low reactogenicity, high safety profile and immunogenicity of the Flu-M vaccine were determined.
About the Authors
I. V. Fel'dblyum
Federal State Educational Institution of Higher Education «Perm State Medical University named after Academician E. A. Wagner» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
S. D. Novgorodova
Federal State Educational Institution of Higher Education «Perm State Medical University named after Academician E. A. Wagner» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
G. M. Ignat'ev
The Federal State Unitary Enterprise «St. Petersburg Research Institute of Vaccines and Serums and the Bacterial Preparation Factory» of the Russian Federal Biomedical Agency Federal Medical Biological Agency
Russian Federation
Russian Federation
S. O. Golodnova
Federal State Educational Institution of Higher Education «Perm State Medical University named after Academician E. A. Wagner» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. P. Trukhin
The Federal State Unitary Enterprise «St. Petersburg Research Institute of Vaccines and Serums and the Bacterial Preparation Factory» of the Russian Federal Biomedical Agency Federal Medical Biological Agency
Russian Federation
Russian Federation
S. Ya Melnikov
The Federal State Unitary Enterprise «St. Petersburg Research Institute of Vaccines and Serums and the Bacterial Preparation Factory» of the Russian Federal Biomedical Agency Federal Medical Biological Agency
Russian Federation
Russian Federation
References
1. Masakova V. L., Erofeeva M. K. Topical issues of the prevention of influenza and acute respiratory viral infection. Farmateka. [Pharmatec]. 2013; 15 (268): 32–35 (in Russian).
2. Melnikov O. A., Averkieva L. V. Modern preparations for treatment of influenza and ARVI. Lechaschii Vrach. [Lechaschii Vrach Journal]. 2011; 8: 11–24 (in Russian).
3. Bektimirov T. A. Vaccine prophylaxis of influenza.Lechaschii Vrach. [Lechaschii Vrach Journal]. 2005. 9: 10–15 (in Russian).
4. Beyer W., Palache A., Osterhaus A. Comparison of serology and reactogenicity between influensa subunit vaccines and whole virus or split vaccines: a review and meta analysis of literature. Clin. Drug. Invest. 1998; 15 (1): 1–12.
5. Vaccines against influenza WHO position paper. November 2012. Wkly. Epidemiol. Rec. 2012; 87 (47): 461–76. PMID: 23210147.
6. Medunitsyn N. V. Vaccinology – 2010. 3rd. edition, pererab. and additional: Moscow; 2010 (in Russian).
7. Medunitsyn N, V., Mironov A. N., Movsesyan A. A. Theory and practice of vaccinology. Moscow; 2015 (in Russian).
8. Gribkova N. V., Shmeleva N. P., Sivets N. V., Dashkevich A. M. Evaluation of the immunogenic activity of influenza vaccine «Fluvaxin» in the 2010–2011 season. Medicinskie novosti. [Medical News]. 2011. 8; 31–32 (in Russian).
9. Gribkova N. V., Shmeleva N. P. Retrospective assessment of flu vaccine prevention «Fluvaxin» in the post-pandemic seasons 2010–2013 in the Republic of Belarus. Medicinskie novosti. [Medical News]. 2014;10: 50–52 (in Russian) .
10. Zverev V. V., Kiselev O. I., Korovkin S. A., Mironov A. N., Melnikov S. Ya., Mikhailova N. A. et al. Clinical study of the new inactivated influenza vaccine «Grifor». Zhurnal mikrobiologii, epidemiilogii i immunologii. [Journal of Microbiology Epidemiology and Immunobiology]. 2009; 2: 35–40 (in Russian).
11. Guidelines for the conduct of clinical trials of medicinal products (immunobiological drugs). Part two. Scientific Center for the Expertise of Medical Use of the Ministry of Healthcare of Russia; 2012 (in Russian).
12. Beran J., Prymula R., Chlibek R., Rychly R., Splino M., Douda P. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996–1997. Cent. Eur. J. Public Health.1998; 6 (4): 269–273.
13. Bricout H., Chabanon Al., Souverain A., Sadorge C., Vesikari T., Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017; 22 (18): pii=30527.
14. Briko N. V., Feldblum I. V., Mikheeva I. V. Vaccine prophylaxis. A manual with a simulation course. Moscow: GEOTAR-Media; 2017 (in Russian).
15. Ярилин А. А. Иммунология. Учебник. Москва. ГЭОТАР-МЕДИА; 2010.
16. Tatochenko V. K., Ozeretsky N. A., Fedorov A. M. Immunoprophylaxis – 2014. Reference book. Moscow; 2014 (in Russian).
Review
For citations:
Fel'dblyum I.V., Novgorodova S.D., Ignat'ev G.M., Golodnova S.O., Trukhin V.P., Melnikov S.Ya. Evaluation of the Reactogenicity, Safety and Immunogenicity of the Domestic Influenza Inactivated Split FLU-M Vaccine in Immunization Adults aged 18–60 Years. Epidemiology and Vaccinal Prevention. 2018;17(1):20-24. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-1-20-24
Views:
2050
Email this article 